ALD1613

ALD1613 is a potent neutralizing monoclonal antibody against adrenocorticotropic hormone (ACTH) . ALD1613 neutralizes ACTH-induced signaling and inhibits ACTH-induced cyclic AMP accumulation in a mouse adrenal cell line (Y1) via all five melanocortin receptors. ALD1613 significantly reduces plasma corticosterone levels in wild-type rats. ALD1613 can be used in the study of diseases associated with elevated ACTH levels[1].

Product Specifications

UNSPSC

12352203

Target

Melanocortin Receptor

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Smiles

[ALD1613]

References & Citations

[1]Andrew L Feldhaus, et al. ALD1613, a Novel Long-Acting Monoclonal Antibody to Control ACTH-Driven Pharmacology. Endocrinology. 2017 Jan 1;158 (1) :1-8.